Molluscum contagiosum

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results

Retrieved on: 
Wednesday, March 2, 2022
NDA, Table, Control, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dermatology, Research, Genetically modified bacteria, Patient, Pharmacokinetics, Adult, Immunotherapy, Food and Drug Administration, Food, Safety, Mission statement, U.S. Securities and Exchange Commission, Skin, Molluscum contagiosum, PDUFA, Silicon, FDA, New Drug Application, Collaboration, Wart, CMC, Company, WEST, Disease, Social stigma, Squamous cell carcinoma, Pain, Inflammation, Sibling, Cantharidin, GAAP, Private Securities Litigation Reform Act, Review, Silicon Valley Bank, Insurance, Fomite, Itch, Achievement, GLOBE, Therapy, Pharmaceutical industry, Bank, Animal, Reinsurance, Chemistry

WEST CHESTER, Pa., March 02, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • The amendment provides Verrica increased financial flexibility by extending the interest-only payment period and reducing the minimum cash Verrica is required to maintain on its balance sheet.
  • Verrica reported a net loss of $9.5 million for the fourth quarter of 2021, compared to a $13.0 million loss for the same period in 2020.
  • Research and development expenses were $3.4million in the fourth quarter of 2021, compared to $2.3 million for the same period in 2020.
  • General and administrative expenses were $5.1million in the fourth quarter of 2021, compared to $9.8 million for the same period in 2020.

Verrica Pharmaceuticals Announces Participation in the 42nd Annual Cowen Virtual Healthcare Conference

Retrieved on: 
Thursday, February 24, 2022
GLOBE, Skin, Therapy, Webcast, Wart, Dermatology, Company, Molluscum contagiosum, Conference, CEO, Pharmaceutical industry, Broadcasting

WEST CHESTER, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 42nd Annual Cowen Virtual Healthcare Conference on Wednesday, March 9, 2022, at 11:10 a.m.

Key Points: 
  • WEST CHESTER, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 42nd Annual Cowen Virtual Healthcare Conference on Wednesday, March 9, 2022, at 11:10 a.m.
  • Participants may access a live webcast of the event through the following link:
    The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com .
  • Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions.
  • Verrica is also developingVP-103,its second cantharidin-based product candidate, for the treatment of plantar warts.

Novan Reports Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, Webcast, Commercial Operating System (COS), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medical Affairs Bureau, Toxicity, Hand, Marketing, COVID-19, Dermatology, Company, Molluscum contagiosum, RDN, Food and Drug Administration, Food, Severe acute respiratory syndrome coronavirus 2, FDA, Conference, Novin, NDA, Manufacturing operations management, Acne, Doctor of Philosophy, Management, Pharmaceutical industry, SB206

DURHAM, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the year ended December 31, 2021 and provided a corporate update. The Company will host a conference call and webcast, today, February 22, 2022, at 8:30 a.m. ET (details below).

Key Points: 
  • ET
    DURHAM, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (the Company or Novan) (Nasdaq: NOVN), today announced its financial and operating results for the year ended December 31, 2021 and provided a corporate update.
  • Melvin Whitehead, who has over 20 years of manufacturing experience within pharma and CDMOs, as Senior Vice President of Manufacturing & Operations.
  • In two previous Phase 3 studies, AC301 and AC302, SB204 demonstrated consistent and promising results across two of three co-primary endpoints.
  • License and collaboration revenue was $2.8 million and $4.2 million for the years ended December 31, 2021 and 2020, respectively.

Global Guanylate Cyclase Activators Pipeline Market Report 2021 Featuring Novan, Radikal Therapeutics, Ironwood Pharmaceuticals, & Bayer - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022
Health, Pharmaceutical, NDA, Guanylate cyclase 2C, Technology, News, Molluscum contagiosum, Clinical trial, Discovery, Activator, Skin infection, Hypertensive emergency, Guanylate cyclase, Skin, Therapy, SB206, GC, II, Administration, Route, Route of administration, Acquisition, Medical imaging, Pharmaceutical industry

This "Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators pipeline landscape.

Key Points: 
  • This "Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators pipeline landscape.
  • A detailed picture of the Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators pipeline landscape is provided which includes the disease overview and Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators treatment guidelines.
  • Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators: Therapeutic Assessment
    This segment of the report provides insights about the different Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference

Retrieved on: 
Friday, January 14, 2022
Grand Promenade, Forward-looking statement, NDA, Patient, Technology, Skin, Conference, BOTE, Annual report, Safety, Inflammation, NCE, Private Securities Litigation Reform Act, COVID-19, Science, Dermatology, Efficacy, GLOBE, Molluscum contagiosum, New chemical entity, U.S. Securities and Exchange Commission, Novin, Company, Caregiver, US Foods, Risk, SB206, FDA, Security (finance), Sodium, Symptoms of COVID-19, Pharmaceutical industry, Medical device

DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (the Company or Novan) (Nasdaq: NOVN), today announced that data from the Companys completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel (previously referred to as SB206) for molluscum contagiosum will be presented at the 2022 Winter Clinical Dermatology Conference, being held January 14-19, 2022, in Koloa, Hawaii.

Key Points: 
  • DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (the Company or Novan) (Nasdaq: NOVN), today announced that data from the Companys completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel (previously referred to as SB206) for molluscum contagiosum will be presented at the 2022 Winter Clinical Dermatology Conference, being held January 14-19, 2022, in Koloa, Hawaii.
  • There is currently no US Food & Drug Administration (FDA) approved medication indicated for the treatment of molluscum.
  • The latter represents a clinical sign of inflammation and imminent resolution of molluscum lesions that has never been prospectively studied in a molluscum clinical trial.
  • For more information about the conference, visit: https://fallclinical.health/
    Novan, Inc. is a pre-commercial nitric oxide-based pharmaceutical company focused on dermatology and anti-infective therapies.

Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Contagiosum

Retrieved on: 
Wednesday, December 15, 2021
Molluscum contagiosum, U.S. Securities and Exchange Commission, Food, Social stigma, FDA, NDA, Dermatology, Company, Pain, New Drug Application, Private Securities Litigation Reform Act, Cantharidin, Skin, Sibling, Prescription Drug User Fee Act, Caregiver, Itch, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Workload, Inflammation, Disease, Therapy, PDUFA, GLOBE, Wart, Genetically modified bacteria, Fomite, Pharmaceutical industry

We are pleased that the FDA has accepted our NDA resubmission for VP-102, said Ted White, Verricas President and Chief Executive Officer.

Key Points: 
  • We are pleased that the FDA has accepted our NDA resubmission for VP-102, said Ted White, Verricas President and Chief Executive Officer.
  • In addition, Verrica has successfully completed a Phase 2 study ofVP-102for the treatment of common warts and a Phase 2 study ofVP-102for the treatment of external genital warts.
  • Without treatment, molluscum can last for an average of 13 months, and in some cases, up to several years.
  • These forward-looking statements include expectations regarding the potential timing and approval of the NDA forVP-102 [and interactions with the FDA].

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Retrieved on: 
Monday, November 29, 2021
Private Securities Litigation Reform Act, Genetically modified bacteria, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Review, Skin, Endpoint security, Industry, Fomite, Company, Wart, Molluscum contagiosum, Dermatology, New Drug Application, Inflammation, Therapy, Pain, Social stigma, CRL, Sibling, GLOBE, Letter, NDA, Cantharidin, FDA, U.S. Securities and Exchange Commission, Element, Itch, Disease, Food, CMO, Pharmaceutical industry

We look forward to the FDAs review of the resubmission of our NDA for VP-102, said Ted White, Verricas President and Chief Executive Officer.

Key Points: 
  • We look forward to the FDAs review of the resubmission of our NDA for VP-102, said Ted White, Verricas President and Chief Executive Officer.
  • Based on published guidance for the industry, we believe our resubmitted NDA qualifies as a Class I resubmission with a 2-month review.
  • If approved, Verrica is well-prepared to launch VP-102 as the first FDA-approved treatment option for molluscum, a highly contagious viral skin disease affecting 6 million people, primarily children, in the U.S. each year.
  • Without treatment, molluscum can last for an average of 13 months, and in some cases, up to several years.

Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

Retrieved on: 
Thursday, November 18, 2021
Patient, Private Securities Litigation Reform Act, Immunogenic cell death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Technology, Â, WEST, Scar, Cancer, Company, Wart, Dermatology, Molluscum contagiosum, Therapy, Pain, Squamous cell carcinoma, Skin, Research, Neoplasm, Mitochondrion, GLOBE, U.S. Securities and Exchange Commission, Immunotherapy, Organelle, Infection, Skin cancer, Basal-cell carcinoma, Food, Medical imaging, Pharmaceutical industry

WEST CHESTER, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted the Company’s Investigational New Drug Application (“IND”) for LTX-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. The Company expects to initiate its Phase 2 trial of LTX-315 in basal cell carcinoma in the first quarter of 2022.

Key Points: 
  • The Company expects to initiate its Phase 2 trial of LTX-315 in basal cell carcinoma in the first quarter of 2022.
  • LTX-315, a non-surgical immunotherapy that targets cancerous skin cells, is a remarkably innovative approach to skin cancer and represents a new treatment paradigm beyond invasive surgery.
  • LTX-315s unique mechanism of action is clearly an innovative approach to potentially provide significant improvement over invasive surgery.
  • It will be an honor to serve as the lead primary investigator in the Verrica LTX-315 trial for the treatment of basal cell carcinoma.

Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results

Retrieved on: 
Friday, November 12, 2021
NDA, Mission statement, Fomite, Safety, Dermatology, Achievement, Cancer, Cantharidin, Skin, Private Securities Litigation Reform Act, CMO, Molluscum contagiosum, Wart, Genetically modified bacteria, Disease, Classification, Skin cancer, Food, Inflammation, Insurance, Endpoint security, Letter, Itch, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Table, Collaboration, VAI, CRL, Control, Squamous cell carcinoma, Company, New Drug Application, Research, Pain, Social stigma, Therapy, GLOBE, U.S. Securities and Exchange Commission, GAAP, Sibling, FDA, CMC, IND, Pharmaceutical industry, Reinsurance, Bank

WEST CHESTER, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2021.

Key Points: 
  • WEST CHESTER, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2021.
  • Following the CRL, on September 22, 2021 Verrica received a General Advice Letter from the FDA with recommendations to improve YCANTHs user interface.
  • Research and development expenses were $3.8million in the third quarter of 2021, compared to $5.0 million for the same period in 2020.
  • General and administrative expenses were $8.0million in the third quarter of 2021, compared to $4.6 million for the same period in 2020.

Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Retrieved on: 
Wednesday, November 10, 2021
NDA, Molluscum contagiosum, MBA, Doctor of Philosophy, Acne, Food, Severe acute respiratory syndrome coronavirus 2, SB206, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, Novin, Company, GLOBE, Toxicity, Webcast, Nasdaq, Marketing, FDA, Sulfur, Management, Pharmaceutical industry

DURHAM, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the quarter ended September 30, 2021 and provided a corporate update. The Company will host a conference call and webcast, today, November 10, 2021, at 8:30 a.m. ET (details below).

Key Points: 
  • ET
    DURHAM, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the Company or Novan) (Nasdaq: NOVN), today announced its financial and operating results for the quarter ended September 30, 2021 and provided a corporate update.
  • Ended the third quarter of 2021 with a total cash and cash equivalents balance of $60.0 million and positive working capital of $48.8 million.
  • As of September 30, 2021, Novan had a total cash and cash equivalents balance of $60.0 million and positive working capital of $48.8 million.
  • During the second quarter of 2021, the Company recognized a $1.0 million gain on debt extinguishment related to the forgiveness of its Paycheck Protection Program loan in June 2021.